Vernon E. Steele

14.3k total citations · 1 hit paper
293 papers, 11.9k citations indexed

About

Vernon E. Steele is a scholar working on Molecular Biology, Cancer Research and Genetics. According to data from OpenAlex, Vernon E. Steele has authored 293 papers receiving a total of 11.9k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Molecular Biology, 84 papers in Cancer Research and 62 papers in Genetics. Recurrent topics in Vernon E. Steele's work include Inflammatory mediators and NSAID effects (56 papers), Estrogen and related hormone effects (50 papers) and Genomics, phytochemicals, and oxidative stress (40 papers). Vernon E. Steele is often cited by papers focused on Inflammatory mediators and NSAID effects (56 papers), Estrogen and related hormone effects (50 papers) and Genomics, phytochemicals, and oxidative stress (40 papers). Vernon E. Steele collaborates with scholars based in United States, Italy and Malaysia. Vernon E. Steele's co-authors include Gary J. Kelloff, Ronald A. Lubet, Chinthalapally V. Rao, James A. Crowell, Caroline C. Sigman, Bandaru S. Reddy, Charles W. Boone, Silvio De Flora, Gary J. Kelloff and Alberto Izzotti and has published in prestigious journals such as PLoS ONE, Development and JNCI Journal of the National Cancer Institute.

In The Last Decade

Vernon E. Steele

292 papers receiving 11.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer.

1999 513 citations Vernon E. Steele, Gary J. Kelloff et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vernon E. Steele United States	57	5.7k	2.8k	2.1k	2.1k	1.9k	293	11.9k
Ronald A. Lubet United States	57	5.4k 1.0×	2.7k 1.0×	3.0k 1.4×	2.3k 1.1×	2.2k 1.2×	344	12.7k
Takuji Tanaka Japan	65	6.6k 1.2×	2.4k 0.9×	2.4k 1.1×	1.7k 0.8×	1.2k 0.6×	409	14.7k
Bandaru S. Reddy United States	76	6.0k 1.1×	3.4k 1.2×	3.3k 1.6×	3.3k 1.5×	2.3k 1.2×	194	15.9k
Sanjay Gupta United States	69	7.2k 1.3×	2.6k 1.0×	1.9k 0.9×	2.7k 1.3×	993 0.5×	286	15.1k
Chinthalapally V. Rao United States	62	6.4k 1.1×	4.2k 1.5×	4.8k 2.3×	3.8k 1.8×	2.1k 1.1×	262	16.9k
Levy Kopelovich United States	50	4.8k 0.9×	1.8k 0.6×	2.5k 1.2×	1.1k 0.5×	1.1k 0.6×	214	9.2k
Kotha Subbaramaiah United States	55	4.0k 0.7×	2.1k 0.8×	2.6k 1.2×	4.9k 2.3×	3.0k 1.6×	118	11.6k
Ann M. Bode United States	77	12.4k 2.2×	3.3k 1.2×	4.1k 1.9×	1.4k 0.7×	811 0.4×	422	21.1k
Shantu Amin United States	60	9.0k 1.6×	3.0k 1.1×	2.3k 1.1×	864 0.4×	808 0.4×	437	15.4k
Thomas E. Eling United States	67	5.7k 1.0×	1.7k 0.6×	1.2k 0.6×	3.5k 1.7×	1.4k 0.7×	294	15.0k

Countries citing papers authored by Vernon E. Steele

Since Specialization

Citations

This map shows the geographic impact of Vernon E. Steele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vernon E. Steele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vernon E. Steele more than expected).

Fields of papers citing papers by Vernon E. Steele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vernon E. Steele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vernon E. Steele. The network helps show where Vernon E. Steele may publish in the future.

Co-authorship network of co-authors of Vernon E. Steele

This figure shows the co-authorship network connecting the top 25 collaborators of Vernon E. Steele. A scholar is included among the top collaborators of Vernon E. Steele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vernon E. Steele. Vernon E. Steele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Madka, Venkateshwar, Gaurav Kumar, Gopal Pathuri, et al.. (2021). Proton Pump Inhibitor Omeprazole Suppresses Carcinogen-induced Colonic Adenoma Progression to Adenocarcinoma in F344 Rat. Cancer Prevention Research. 14(11). 1009–1020. 6 indexed citations

Madka, Venkateshwar, Gaurav Kumar, Gopal Pathuri, et al.. (2019). Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model. Cancer Prevention Research. 13(2). 185–194. 9 indexed citations

Wuertz, Beverly R., et al.. (2019). Chemoprevention of Lung Carcinogenesis by Dietary Nicotinamide and Inhaled Budesonide. Cancer Prevention Research. 12(2). 69–78. 9 indexed citations

Lubet, Ronald A., Vernon E. Steele, Robert H. Shoemaker, & Clinton J. Grubbs. (2018). Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression. Cancer Prevention Research. 11(10). 595–606. 4 indexed citations

Antonides, Jennifer D., Beverly R. Wuertz, Wendy A. Miller, et al.. (2017). Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention. Cancer Prevention Research. 10(2). 116–123. 21 indexed citations

Lubet, Ronald A., Reid Townsend, Margie L. Clapper, et al.. (2016). 5MeCDDO Blocks Metabolic Activation but not Progression of Breast, Intestine, and Tongue Cancers. Is Antioxidant Response Element a Prevention Target?. Cancer Prevention Research. 9(7). 616–623. 6 indexed citations

Janakiram, Naveena B., Altaf Mohammed, Stan Lightfoot, et al.. (2015). Improved Innate Immune Responses by Frondanol A5, a Sea Cucumber Extract, Prevent Intestinal Tumorigenesis. Cancer Prevention Research. 8(4). 327–337. 25 indexed citations

Madka, Venkateshwar, Altaf Mohammed, Qian Li, et al.. (2015). Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo. Cancer Prevention Research. 9(1). 53–62. 13 indexed citations

Lubet, Ronald A., James M. Scheiman, Ann M. Bode, et al.. (2015). Prevention of Chemically Induced Urinary Bladder Cancers by Naproxen: Protocols to Reduce Gastric Toxicity in Humans Do Not Alter Preventive Efficacy. Cancer Prevention Research. 8(4). 296–302. 13 indexed citations

10.

Mohammed, Altaf, Naveena B. Janakiram, Venkateshwar Madka, et al.. (2014). Eflornithine (DFMO) Prevents Progression of Pancreatic Cancer by Modulating Ornithine Decarboxylase Signaling. Cancer Prevention Research. 7(12). 1198–1209. 55 indexed citations

11.

Lubet, Ronald A., Éva Szabó, Kenneth K. Iwata, et al.. (2013). Effect of Intermittent Dosing Regimens of Erlotinib on Methylnitrosourea-Induced Mammary Carcinogenesis. Cancer Prevention Research. 6(5). 448–454. 11 indexed citations

12.

Nicastro, Holly L., Clinton J. Grubbs, M. Margaret Juliana, et al.. (2013). Preventive Effects of NSAIDs, NO-NSAIDs, and NSAIDs Plus Difluoromethylornithine in a Chemically Induced Urinary Bladder Cancer Model. Cancer Prevention Research. 7(2). 246–254. 20 indexed citations

13.

Mohammed, Altaf, Naveena B. Janakiram, Qian Li, et al.. (2011). Chemoprevention of Colon and Small Intestinal Tumorigenesis in APCMin/+ Mice by Licofelone, a Novel Dual 5-LOX/COX Inhibitor: Potential Implications for Human Colon Cancer Prevention. Cancer Prevention Research. 4(12). 2015–2026. 51 indexed citations

14.

Mohammed, Altaf, Naveena B. Janakiram, Venkateshwar Madka, et al.. (2010). The Epidermal Growth Factor Receptor Inhibitor Gefitinib Prevents the Progression of Pancreatic Lesions to Carcinoma in a Conditional LSL-KrasG12D/+ Transgenic Mouse Model. Cancer Prevention Research. 3(11). 1417–1426. 45 indexed citations

15.

Rao, Chinthalapally V., Vernon E. Steele, Malisetty V. Swamy, et al.. (2009). Inhibition of Azoxymethane-Induced Colorectal Cancer by CP-31398, a TP53 Modulator, Alone or in Combination with Low Doses of Celecoxib in Male F344 Rats. Cancer Research. 69(20). 8175–8182. 27 indexed citations

16.

Tao, Lianhui, Wei Wang, Paula M. Kramer, et al.. (2004). Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer. Molecular Carcinogenesis. 39(2). 79–84. 14 indexed citations

17.

Rodríguez-Burford, Cristina, Vernon E. Steele, Amy Anderson, et al.. (2002). Effects of Body Weight Gain Reduction Resulting From Chemopreventive Agent Treatment on Mammary Gland Morphology. Nutrition and Cancer. 43(1). 67–75. 3 indexed citations

18.

Elmore, Eugene, et al.. (2001). Comparative Tissue-Specific Toxicities of 20 Cancer Preventive Agents Using Cultured Cells From 8 Different Normal Human Epithelia. PubMed. 14(3). 191–207. 11 indexed citations

19.

Gupta, Amod, Peter S. Carlton, Diana L. Gray, et al.. (2001). Effects of Dietary N-(4-Hydroxyphenyl)retinamide on N-Nitrosomethylbenzylamine Metabolism and Esophageal Tumorigenesis in the Fischer 344 Rat. JNCI Journal of the National Cancer Institute. 93(13). 990–998. 10 indexed citations

20.

Kelloff, Gary J., James A. Crowell, Vernon E. Steele, et al.. (2000). Progress in Cancer Chemoprevention: Development of Diet-Derived Chemopreventive Agents. Journal of Nutrition. 130(2). 467S–471S. 382 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact